Filing Flows › Comparisons › PCRX vs RARE
Pacira BioSciences vs Ultragenyx Pharmaceutical: PCRX and RARE compared
Pacira BioSciences is the larger company: $177M of revenue in its latest quarter (Q3 2026) against $173M for Ultragenyx Pharmaceutical (Q3 2026). Ultragenyx Pharmaceutical is growing faster (+8% against -2% a year earlier). Pacira BioSciences is more profitable, with an operating margin of 12.6% against -63.6%.
Where the money goes: PCRX and RARE
Pacira BioSciences (PCRX) · Q3 2026
Pacira BioSciences, Q3 2026: revenue $177M (-2% year over year), operating margin 12.6%, net earnings $28.5M, operating cash flow $50.1M. The chart follows the revenue to costs, profit and cash.
Ultragenyx Pharmaceutical (RARE) · Q3 2026
Ultragenyx Pharmaceutical, Q3 2026: revenue $173M (+8% year over year), operating margin -63.6%, net loss $118M, operating cash flow −$43.0M. The chart follows the revenue to costs, profit and cash.
| Pacira BioSciences (PCRX) | Ultragenyx Pharmaceutical (RARE) | |
|---|---|---|
| Latest quarter | Q3 2026 | Q3 2026 |
| Revenue | $177M | $173M |
| Revenue growth, Y/Y | -2% | +8% |
| Operating margin | 12.6% | -63.6% |
| Net earnings | $28.5M | −$118M |
| Net margin | 16.1% | -68.2% |
| Operating cash flow | $50.1M | −$43.0M |
| Free cash flow | $46.4M | — |
| Market value | $1.5B | $1.6B |
| P/E | 100.3× | — |
| Analysts’ mean target | $33.57 | $25.40 |
Where the revenue comes from
Pacira BioSciences
- Net product sales: $175M (99%)
- Bupivacaine liposome injectable suspension: $1.2M (1%)
Ultragenyx Pharmaceutical
- Product: $105M (61%)
- Royalty: $68.0M (39%)
Questions
Which is bigger, Pacira BioSciences or Ultragenyx Pharmaceutical?
Pacira BioSciences is the larger company: $177M of revenue in its latest quarter (Q3 2026) against $173M for Ultragenyx Pharmaceutical (Q3 2026).
Is Pacira BioSciences or Ultragenyx Pharmaceutical growing faster?
Ultragenyx Pharmaceutical is growing faster (+8% against -2% a year earlier).
Which is more profitable, Pacira BioSciences or Ultragenyx Pharmaceutical?
Pacira BioSciences is more profitable, with an operating margin of 12.6% against -63.6%.
More: Pacira BioSciences earnings · how Pacira BioSciences makes money · Ultragenyx Pharmaceutical earnings · how Ultragenyx Pharmaceutical makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Nov 5, 2026; 10-Q filed Nov 4, 2026). Fiscal quarters can end on different dates. Not investment advice.